Phase III Study to Evaluate Efficacy and Safety of DSC127 in Diabetic Foot Ulcers

PHASE3TerminatedINTERVENTIONAL
Enrollment

266

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Diabetic Foot Ulcers
Interventions
DRUG

DSC127

DSC127 0.03%, daily topical application to diabetic foot ulcer for a period of up to 28 days or until ulcer closure, whichever is sooner

DRUG

placebo vehicle gel

Trial Locations (25)

24016

Professional Education and Research Institute, Roanoke

27834

East Carolina Foot and Ankle Specialists, Greenville

29801

Carolina Musculoskeletel Institute, Aiken

32209

UF Health Orthopaedic Surgery Clinic, Jacksonville

33013

Barry University Clinical Research, North Miami Beach

33016

GF Professional Research, Miami Lakes

33030

Advanced Research Institute of Miami, Homestead

33176

Miami Dade Medical Research Institute, Miami

33713

Professional Health Care of Pinellas, St. Petersburg

36680

WILMAX Clinical Research Inc, Mobile

37421

ClinSearch, LLC, Chattanooga

46350

LaPorte Medical Group, La Porte

46530

Memorial Medical Group, Granger

75216

Dallas VA Medical Center, Dallas

76104

Fort Worth Diagnostic Clinic, Fort Worth

78229

Endeavor Clinical Trials, San Antonio

90010

Foot and Ankle Clinic, Los Angeles

91342

UCLA Medical Center - Olive View, Sylmar

92780

Orange County Research Center, Tustin

93449

Brian O'Carroll, DPM, Inc., Pismo Beach

93710

Roy O Kroeker, DPM, Inc, Fresno

95628

Center for Clinical Research, Fair Oaks

97232

Center for Clinical Research, Portland

97401

Clinical Research Center, Eugene

02118

Boston University Medical Center, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Integrium

INDUSTRY

lead

Integra LifeSciences Corporation

INDUSTRY

NCT01830348 - Phase III Study to Evaluate Efficacy and Safety of DSC127 in Diabetic Foot Ulcers | Biotech Hunter | Biotech Hunter